PMC:6723065 / 18447-19332 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6723065","sourcedb":"PMC","sourceid":"6723065","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6723065","text":"l-dopa formulations are generally associated with a peripheral Dopa decarboxylase inhibitors (more frequently carbidopa or benserazide) in order to inhibit peripheral metabolism of l-dopa. Slight differences in terms of tolerability are associated with the treatment with l-dopa + benserazide (Madopar) compared to l-dopa + carbidopa (Sinemet). In a triple-blind trial [79], patients were allocated at random to treatment with either l-dopa + benserazide ratio 4:1 (Madopar) or l-dopa + carbidopa ratio 10:1 (Sinemet) using dosage schedules recommended by the manufacturers which they had to adhere to for 6 months. Results showed that the effect of the two schedules on the parkinsonian symptoms were equal and they appeared equally fast but the frequency of gastrointestinal side-effects and involuntary movements seemed higher and more severe for Sinemet than for the Madopar group.","tracks":[{"project":"2_test","denotations":[{"id":"31434341-1266576-7278282","span":{"begin":370,"end":372},"obj":"1266576"}],"attributes":[{"subj":"31434341-1266576-7278282","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#9b93ec","default":true}]}]}}